Treatment of small cell lung cancer in the elderly

The progress and limitation of chemotherapy

T. Ohnoshi, h. Ueoka, N. Hino, T. Yonei, T. Horiguchi, Katsuyuki Kiura, T. Moritaka, T. Kodani, H. Kamei, Y. Segawa, T. Maeda, Masahiro Tabata, T. Shibayama, K. Miyatake, N. Takigawa, I. Kimura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In order to assess the progress and limitation of chemotherapy in the treatment of small cell lung cancer in the elderly, we analyzed 218 patients who had entered into protocol studies between 1982 and 1990. Among those, there were 101 elderly patients (age of ≥66 years) and 117 non-elderly patients (age of ≤65 years). Response to chemotherapy with or without chest irradiation was almost comparable for the elderly and the non-elderly; complete response rate was 52% for limited disease (LD) and 33% for extensive disease (ED) in the elderly, and it was 68% for LD and 23% for ED in the non-elderly. Survival figures of the two groups were quite similar. The median survival time was 12.6 months for the elderly and 14.5 months for the non-elderly, and the 3-year survival rate was 14% for both groups. An improvement of patient survival was observed along with the chronology of the protocols, i.e., with an escalation of dose intensity. Of interest, the improvement was rather evident in the elderly than in the non-elderly. Hematologic toxicity was considerably more frequent and severe in the elderly than in the non-elderly with non-significant statistics. The incidence of fever episodes while neutropenic was significantly more frequent in the elderly. Non-hematologic toxicity was almost comparable for the two groups, with an exception that the elderly showed a trend being predisposed to renal toxicity. In conclusion, such elderly patients as eligible for entry into a protocol study can benefit from intensive treatment as equally as non-elderly patients can.

Original languageEnglish
Pages (from-to)216-223
Number of pages8
JournalJapanese Journal of Thoracic Diseases
Volume30
Issue number2
Publication statusPublished - 1992

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Therapeutics
Survival
Chronology
Fever
Thorax
Survival Rate
Kidney
Incidence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ohnoshi, T., Ueoka, H., Hino, N., Yonei, T., Horiguchi, T., Kiura, K., ... Kimura, I. (1992). Treatment of small cell lung cancer in the elderly: The progress and limitation of chemotherapy. Japanese Journal of Thoracic Diseases, 30(2), 216-223.

Treatment of small cell lung cancer in the elderly : The progress and limitation of chemotherapy. / Ohnoshi, T.; Ueoka, h.; Hino, N.; Yonei, T.; Horiguchi, T.; Kiura, Katsuyuki; Moritaka, T.; Kodani, T.; Kamei, H.; Segawa, Y.; Maeda, T.; Tabata, Masahiro; Shibayama, T.; Miyatake, K.; Takigawa, N.; Kimura, I.

In: Japanese Journal of Thoracic Diseases, Vol. 30, No. 2, 1992, p. 216-223.

Research output: Contribution to journalArticle

Ohnoshi, T, Ueoka, H, Hino, N, Yonei, T, Horiguchi, T, Kiura, K, Moritaka, T, Kodani, T, Kamei, H, Segawa, Y, Maeda, T, Tabata, M, Shibayama, T, Miyatake, K, Takigawa, N & Kimura, I 1992, 'Treatment of small cell lung cancer in the elderly: The progress and limitation of chemotherapy', Japanese Journal of Thoracic Diseases, vol. 30, no. 2, pp. 216-223.
Ohnoshi, T. ; Ueoka, h. ; Hino, N. ; Yonei, T. ; Horiguchi, T. ; Kiura, Katsuyuki ; Moritaka, T. ; Kodani, T. ; Kamei, H. ; Segawa, Y. ; Maeda, T. ; Tabata, Masahiro ; Shibayama, T. ; Miyatake, K. ; Takigawa, N. ; Kimura, I. / Treatment of small cell lung cancer in the elderly : The progress and limitation of chemotherapy. In: Japanese Journal of Thoracic Diseases. 1992 ; Vol. 30, No. 2. pp. 216-223.
@article{bb3340cfe8d24d4388cbdf84f5dc2e43,
title = "Treatment of small cell lung cancer in the elderly: The progress and limitation of chemotherapy",
abstract = "In order to assess the progress and limitation of chemotherapy in the treatment of small cell lung cancer in the elderly, we analyzed 218 patients who had entered into protocol studies between 1982 and 1990. Among those, there were 101 elderly patients (age of ≥66 years) and 117 non-elderly patients (age of ≤65 years). Response to chemotherapy with or without chest irradiation was almost comparable for the elderly and the non-elderly; complete response rate was 52{\%} for limited disease (LD) and 33{\%} for extensive disease (ED) in the elderly, and it was 68{\%} for LD and 23{\%} for ED in the non-elderly. Survival figures of the two groups were quite similar. The median survival time was 12.6 months for the elderly and 14.5 months for the non-elderly, and the 3-year survival rate was 14{\%} for both groups. An improvement of patient survival was observed along with the chronology of the protocols, i.e., with an escalation of dose intensity. Of interest, the improvement was rather evident in the elderly than in the non-elderly. Hematologic toxicity was considerably more frequent and severe in the elderly than in the non-elderly with non-significant statistics. The incidence of fever episodes while neutropenic was significantly more frequent in the elderly. Non-hematologic toxicity was almost comparable for the two groups, with an exception that the elderly showed a trend being predisposed to renal toxicity. In conclusion, such elderly patients as eligible for entry into a protocol study can benefit from intensive treatment as equally as non-elderly patients can.",
author = "T. Ohnoshi and h. Ueoka and N. Hino and T. Yonei and T. Horiguchi and Katsuyuki Kiura and T. Moritaka and T. Kodani and H. Kamei and Y. Segawa and T. Maeda and Masahiro Tabata and T. Shibayama and K. Miyatake and N. Takigawa and I. Kimura",
year = "1992",
language = "English",
volume = "30",
pages = "216--223",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Treatment of small cell lung cancer in the elderly

T2 - The progress and limitation of chemotherapy

AU - Ohnoshi, T.

AU - Ueoka, h.

AU - Hino, N.

AU - Yonei, T.

AU - Horiguchi, T.

AU - Kiura, Katsuyuki

AU - Moritaka, T.

AU - Kodani, T.

AU - Kamei, H.

AU - Segawa, Y.

AU - Maeda, T.

AU - Tabata, Masahiro

AU - Shibayama, T.

AU - Miyatake, K.

AU - Takigawa, N.

AU - Kimura, I.

PY - 1992

Y1 - 1992

N2 - In order to assess the progress and limitation of chemotherapy in the treatment of small cell lung cancer in the elderly, we analyzed 218 patients who had entered into protocol studies between 1982 and 1990. Among those, there were 101 elderly patients (age of ≥66 years) and 117 non-elderly patients (age of ≤65 years). Response to chemotherapy with or without chest irradiation was almost comparable for the elderly and the non-elderly; complete response rate was 52% for limited disease (LD) and 33% for extensive disease (ED) in the elderly, and it was 68% for LD and 23% for ED in the non-elderly. Survival figures of the two groups were quite similar. The median survival time was 12.6 months for the elderly and 14.5 months for the non-elderly, and the 3-year survival rate was 14% for both groups. An improvement of patient survival was observed along with the chronology of the protocols, i.e., with an escalation of dose intensity. Of interest, the improvement was rather evident in the elderly than in the non-elderly. Hematologic toxicity was considerably more frequent and severe in the elderly than in the non-elderly with non-significant statistics. The incidence of fever episodes while neutropenic was significantly more frequent in the elderly. Non-hematologic toxicity was almost comparable for the two groups, with an exception that the elderly showed a trend being predisposed to renal toxicity. In conclusion, such elderly patients as eligible for entry into a protocol study can benefit from intensive treatment as equally as non-elderly patients can.

AB - In order to assess the progress and limitation of chemotherapy in the treatment of small cell lung cancer in the elderly, we analyzed 218 patients who had entered into protocol studies between 1982 and 1990. Among those, there were 101 elderly patients (age of ≥66 years) and 117 non-elderly patients (age of ≤65 years). Response to chemotherapy with or without chest irradiation was almost comparable for the elderly and the non-elderly; complete response rate was 52% for limited disease (LD) and 33% for extensive disease (ED) in the elderly, and it was 68% for LD and 23% for ED in the non-elderly. Survival figures of the two groups were quite similar. The median survival time was 12.6 months for the elderly and 14.5 months for the non-elderly, and the 3-year survival rate was 14% for both groups. An improvement of patient survival was observed along with the chronology of the protocols, i.e., with an escalation of dose intensity. Of interest, the improvement was rather evident in the elderly than in the non-elderly. Hematologic toxicity was considerably more frequent and severe in the elderly than in the non-elderly with non-significant statistics. The incidence of fever episodes while neutropenic was significantly more frequent in the elderly. Non-hematologic toxicity was almost comparable for the two groups, with an exception that the elderly showed a trend being predisposed to renal toxicity. In conclusion, such elderly patients as eligible for entry into a protocol study can benefit from intensive treatment as equally as non-elderly patients can.

UR - http://www.scopus.com/inward/record.url?scp=0026510278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026510278&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 216

EP - 223

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 2

ER -